肺癌ppt课件(1)PPT文档格式.ppt
- 文档编号:814809
- 上传时间:2023-04-29
- 格式:PPT
- 页数:65
- 大小:8.54MB
肺癌ppt课件(1)PPT文档格式.ppt
《肺癌ppt课件(1)PPT文档格式.ppt》由会员分享,可在线阅读,更多相关《肺癌ppt课件(1)PPT文档格式.ppt(65页珍藏版)》请在冰点文库上搜索。
38.86辽宁:
32.07黑龙江:
29.06吉林:
28.06云南:
23.07北京:
22.25内蒙古:
22.04,肺癌的流行病学特点,解剖和病理AnatomyandPathology,肺癌的分类学,按部位分:
中央型周围型按生物学分:
小细胞肺癌:
(15-20%)非小细胞肺癌:
(80-85%)鳞癌腺癌大细胞癌腺鳞癌其它,肺癌病理类型,鳞癌0.30-0.35腺癌0.35-0.40大细胞癌0.10小细胞癌0.20-0.25,症状和诊断SymptomsandDiagnosis,肺癌的症状学,发生发展表现肺癌形成无症状累及小支气管咳嗽累及粘膜微血管血痰侵及胸膜胸壁胸闷胸痛阻塞支气管气促发热胸膜播散胸水非特异性症状:
食欲不振体重下降,肺癌的症状学,外侵和转移症状上腔静脉综合征HornersSyndromePancoastsSyndrome肺癌伴随症状:
肺性骨关节病类癌综合征男性乳房发育,肺癌的主要症状和体征,0,20,40,60,80,100,咯血,纳差,疼痛,咳嗽,呼吸困难,患者(%),Hollenetal1999,Transthoracicneedleaspiration(TTNA)ofanon-smallcellPancoasttumor,肺癌的诊断学,几个需要遵循的原则警惕经治未愈的呼吸道症状注意少见的肺外表现从常规到复杂从无创到有创重视获取病理学诊断细胞学,组织学,非小细胞肺癌的诊断,Physicalexamination,Detectsigns,Visualizeandsamplemediasturiallymphnodes,Detectposition,size,numberoftumors,Detectchestwallinvasionmediastinallymphodenopathydistantmetastases,Lymphnodestaging,Detectchangesinhormoneproduction,andhematologicalmanifestationsoflungcancer,Preciselocationoftumorobtainbiopsy,ChestX-ray,CTscan,PETscan,Laboratoryanalysis,Bronchoscopy,Mediastinoscopy,FNA,Cytology,NCCNGuidelines2000,诊断(Diagnosis)1、CXR,CT,B2、对肺周围型病变经皮肺穿刺是合适的,但非强制性,特别是既往胸片检查无病变者。
B3、CT提示纵隔淋巴结1cm(短径)应行纵隔镜检,前纵隔切开活检或穿刺。
BBTSGuidelinesThorax2001,5689-108,非小细胞肺癌X线胸片,非小细胞肺癌CT扫描,纵隔镜检查,分期和预后stagingandprognostication,Mountain1997,非小细胞肺癌分期,DiseaseEarlyLocalizedAdvanced,Stage0IAIBIIAIIBIIIAIIIBIV,TNMTISN0M0(carcinomainsitu)T1N0M0T2N0M0T1N1M0T2N1M0T3N0M0T3N1M0T1-3N2M0T4,AnyN,M0AnyT,N3,M0AnyT,AnyN,M1,非小细胞肺癌分期,Stage0,StageIA,StageIIB,StageIIIB,StageIV,Lymphnodes,Mainbronchus,Contralaterallymphnode,Metastasistodistantorgans,Invasionofchestwall,非小细胞肺癌:
临床分期与预后,1year,3years,5years,0,10,20,30,40,50,60,70,80,90,100,IA,IB,IIA,T2N1M0,IV,IIB,IIIA,IIIB,Clinicalstageatpresentation,Survival(%),Mountain1997,T3N0M0,T3N1M0,T1-3N2M0,T4,N3,Probabilityofsurvivalaccordingtoclinicalstage,非小细胞肺癌:
其他影响预后因素可手术(0-IIIA期),肺部症状肿瘤的最大径erbB-2,p53过表达血管侵犯肿瘤血管形成,Harpole1995,非小细胞肺癌:
其他影响预后因素不可手术(IIIB-IV期),PS评分年龄和性别体重下降转移灶LDH,AKP(碱性磷酸酶),血钙,血红蛋白含铂化疗方案,Albainetal1991,治疗Treatment,肺癌治疗思维决策,先进行肺癌的生物学分类小细胞肺癌非小细胞肺癌再根据资料作肺癌的分期决定肺癌的治疗方案治疗结束安排随防计划,非小细胞肺癌:
治疗概况,肿瘤局限手术肿瘤范围较大化疗,放疗(手术)晚期肿瘤化疗,PDQGuidelines,非小细胞肺癌的治疗:
0期,肺叶,肺段切除术,或楔形切除术根治性化疗(有手术禁忌者)内镜下光动力学治疗(疗效待评估),PDQGuidelines,非小细胞肺癌的治疗:
I期和II期,肺叶切除术或肺切除术根治性化疗(有手术禁忌者)辅助化疗辅助放疗新辅助化疗,PDQGuidelines,I期非小细胞肺癌:
手术,Locoregionalrecurrencerate(perperson-year),Locoregionalrecurrencerate(%ofpatients),0,10,20,30,40,50,Segmen-tectomy(n=68),Lobectomy(n=105),00.0,0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,0.10,Limitedresection(n=122),Lobectomy(n=125),p=0.008,WarrenandFaber1994,GinsbergandRubinstein1995,p0.05,I期和II期非小细胞肺癌:
放疗,Dosoretzetal1992,0,10,20,30,40,50,60,70,80,Overall,65Gray,60Gray,Radiationdose,Disease-freesurvival(%),非小细胞肺癌的治疗:
III期,单纯手术治疗(部分IIIA期患者)术后放疗化疗+放疗单纯放疗单纯化疗(IIIB期伴恶性胸腔积液),PDQGuidelines,III期非小细胞肺癌:
手术联合其他治疗,StudyPassetal1992Rothetal1994Roselletal1994,RegimensSurgerypluschemotherapy(n=13)Surgeryplusradiotherapy(n=14)Surgerypluschemotherapy(n=28)Surgeryalone(n=32)Surgeryplusradiotherapypluschemotherapy(n=30)Surgeryplusradiotherapy(n=30),Mediansurvival(months)28.715.66411268,pvalue0.0950.0080.001,I-IIIB期非小细胞肺癌:
CHART,0,10,20,30,40,50,60,70,1-year,2-year,Survival(%patients),Saundersetal1997,p=0.004,III期非小细胞肺癌:
联合放、化疗,NSCLCCollaborativeGroup1995,IV期非小细胞肺癌的治疗,化疗(含铂方案),有生存获益新一代化疗药物外放射治疗(姑息治疗)内镜下激光治疗或近距离化疗(解除气道阻塞),PDQGuidelines,IV期非小细胞肺癌:
联合化疗,0,5,10,15,20,25,30,35,PVp,PVpm,PVe,PVeMi,FOMi/CAP,Responserate(%),p0.001acrosstreatments,0,1,2,3,4,5,6,7,8,9,10,PVp,PVpm,PVe,PVeMi,FOMi/CAP,Mediansurvival(months),p=0.61acrosstreatments,Weicketal1991,IV期非小细胞肺癌:
新一代化疗药物,Paclitaxel,vinorelbine,docetaxelGemcitabine,topotecan,irinotecan单药疗效优于顺铂联合化疗:
在研,Jassem1999,晚期非小细胞肺癌的联合化疗:
近年的随机试验
(1),StudyLeChevalieretal1994Bonomietal1996Crinoetal1998Belanietal1998Cardenaletal1999,RegimensVindesine/cisplatinVinorelbine/cisplatinEtoposide/cisplatinPaclitaxel(135)/cisplatinPaclitaxel(250)/cisplatin/G-CSFMitomycin/ifosfamide/cisplatinGemcitabine/cisplatinEtoposide/cisplatinPaclitaxel/cisplatinEtoposide/cisplatinGemcitabine/cisplatin,Mediansurvival(months)7.69.5*7.69.5*9.9*9.68.68.27.77.28.7,1-yearsurvival(%)2837323739343337322632,Tumorresponse(%)1930*12*27*32*2638*1423*21.940.6*,*p0.05,Gandaraetal1999,晚期非小细胞肺癌的联合化疗:
近年的随机试验
(2),StudyKellyetal1999Schilleretal2000,RegimensVinorelbine(25)/cisplatin(100)Paclitaxel(225)/carboplatin(AUC6)Paclitaxel(135)/cisplatin(75)Gemcitabine(1000)/cisplatin(100)Docetaxel(75)/cisplatin(75)Paclitaxel(225)/carboplatin(AUC6),Mediansurvival(months)887.88.17.48.2,Tumorresponse(%)272721.321.017.315.3,Schilleretal2000,Kellyetal1999,非小细胞肺癌化疗后复发,手术(部分伴局限脑转移灶)姑息放疗姑息化疗内镜下激光治疗或组织内放疗,PDQGuidelines,顺铂耐药,Significantprobleminmanysolidtumors,includingNSCLCMultifactorial:
reducedtransportintocellsdeactivationbyintracellularthiolsincreasedDNArepairincreasedDNAdamagetolerance,Perez1997,展望未来Futuredevelopments,非小细胞肺癌:
未来发展,目前的治疗方案疗效欠佳预防早期诊断提高治疗疗效,PDQGuidelines,预防,教育避免环境致癌物,如吸烟化学预防?
vitaminA异维甲酸,早期诊断,阻塞性肺部疾病遗传危险因素痰脱落细胞学分子肿瘤标记物CT扫描PET,Edell1997,治疗,NSCLC,Novelbiologicaltargets,Immunology:
-interleukins-interferons-vaccines,Newchemotherapydrugs,Genetherapy:
-interleukins-K-ras,新的化疗方法,拓扑异构酶抑制剂新的抗叶酸剂,新的生物学治疗方法,表皮生长因子酪氨酸激酶抑制剂(EGF-TKIs)抗血管治疗金属蛋白酶抑制剂,克服顺铂耐药,Chemopotentiators多聚铂酸盐类不同的DNA结合方式克服巯基失活,免疫治疗和基因治疗,免疫调节剂干扰素,白介素疫苗被动免疫主动免疫基因治疗?
癌基因,如K-ras免疫调节剂,如白介素,
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 肺癌 ppt 课件